The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Beyond biomarker testing: Aligning the needs of oncologist and diagnostic companies to improve biomarker results reports for accurate clinical treatment selection.

Christine M.  Lovly

Honoraria - Amgen; AstraZeneca; Blueprint Medicines; Cepheid; D2G Oncology; Daiichi Sankyo/Astra Zeneca; EMD Serono; Foundation Medicine; Genentech; Janssen Oncology; Lilly; Pfizer; Puma Biotechnology; Syros Pharmaceuticals; Syros Pharmaceuticals; Takeda

Research Funding - AstraZeneca (Inst); Novartis; Xcovery

(OPTIONAL) Uncompensated Relationships - Roche/Genentech

Nikki A.  Martin

Stock and Other Ownership Interests  - Novartis

Upal Kunal  Basu Roy

Honoraria - AstraZeneca (Inst); AstraZeneca/MedImmune

Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Genentech (Inst); Janssen Oncology (Inst); Merck (Inst); Takeda (Inst)